Meenu Karson
Chief Executive Officer bij Onsero Therapeutics Inc
Profiel
Meenu Karson currently works at Onsero Therapeutics Inc, as President & Chief Executive Officer from 2021, Vasomune Therapeutics, Inc., as Director, and Fore Biotherapeutics, Inc., as Director.
Ms. Karson also formerly worked at Allozyne, Inc., as President & Chief Executive Officer from 2007 to 2014, Proteostasis Therapeutics, Inc., as President & Chief Executive Officer from 2014 to 2020, Apexigen, Inc., as Chairman from 2022 to 2023, Vallon Pharmaceuticals, Inc., as Director, BioXell SpA, as Chief Business Officer, and Novartis AG, as VP-Business Development & Licensing.
Ms. Karson received her undergraduate degree from the University of Toronto and Masters Business Admin degree from The Schulich School of Business.
Actieve functies van Meenu Karson
| Bedrijven | Functie | Begin |
|---|---|---|
Fore Biotherapeutics, Inc.
 Fore Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Fore Biotherapeutics, Inc. develops tumor specific driver mutations. It offers fully automated live-cell screening from NGS data. The company was founded by Haim Gil-Ad and Yoram Altschuler in 2011 and is headquartered in Philadelphia, PA. | Director/Board Member | - |
Vasomune Therapeutics, Inc.
 Vasomune Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Vasomune Therapeutics, Inc. operates as an early stage biopharmaceutical company. It develops medicines to harness the body’s ability to defend against illness by modifying cellular response to disease. The company is headquartered in Toronto, Canada. | Director/Board Member | - |
Onsero Therapeutics Inc
 Onsero Therapeutics Inc Miscellaneous Commercial ServicesCommercial Services Onsero Therapeutics Inc is a preclinical neurobiology company that focuses on discovering and developing small molecule drugs to treat a range of neuropsychiatric and mental health conditions by targeting G-protein-coupled receptors (GPCRs). The company is based in Boston, MA. The company's mission is to provide safe and convenient pharmaceutical options to patients. Meenu Karson has been the CEO of the company since 2021. | Chief Executive Officer | 01-07-2021 |
Eerdere bekende functies van Meenu Karson
| Bedrijven | Functie | Einde |
|---|---|---|
| APEXIGEN, INC. | Chairman | 23-08-2023 |
| GRI BIOPAR | Director/Board Member | 21-04-2023 |
| PROTEOSTASIS THERAPEUTICS, INC. | Chief Executive Officer | 01-12-2020 |
Allozyne, Inc.
 Allozyne, Inc. Medical SpecialtiesHealth Technology Allozyne, Inc. operates as a biotechnology company that develops and manufactures pharmaceutical products. The firm focuses on manufacture of protein therapeutics for the medical need in autoimmune diseases and cancer. The company was founded by David A. Tirrell, Deepshikha Datta, and William A. Goddard, III in March 2004 and is headquartered in Seattle, WA. | Chief Executive Officer | 02-01-2014 |
BioXell SpA
 BioXell SpA BiotechnologyHealth Technology BioXell SpA provides medical services. The company researches and develops drugs to treat urological, inflammatory, and related disorders. The company was founded in 2002 and is headquartered in Segrate, Italy. | Corporate Officer/Principal | - |
Opleiding van Meenu Karson
| University of Toronto | Undergraduate Degree |
| The Schulich School of Business | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| NOVARTIS AG | Health Technology |
| APEXIGEN, INC. | Health Technology |
| Bedrijven in privébezit | 7 |
|---|---|
BioXell SpA
BioXell SpA BiotechnologyHealth Technology BioXell SpA provides medical services. The company researches and develops drugs to treat urological, inflammatory, and related disorders. The company was founded in 2002 and is headquartered in Segrate, Italy. | Health Technology |
Allozyne, Inc.
Allozyne, Inc. Medical SpecialtiesHealth Technology Allozyne, Inc. operates as a biotechnology company that develops and manufactures pharmaceutical products. The firm focuses on manufacture of protein therapeutics for the medical need in autoimmune diseases and cancer. The company was founded by David A. Tirrell, Deepshikha Datta, and William A. Goddard, III in March 2004 and is headquartered in Seattle, WA. | Health Technology |
Proteostasis Therapeutics, Inc.
 Proteostasis Therapeutics, Inc. BiotechnologyHealth Technology Proteostasis Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It engages in the discovery and development of novel therapeutics to treat cystic fibrosis (CF) and other diseases caused by an imbalance in the proteostasis network. The company was founded by William Balch, Jeffery W. Kelly, Andrew Dillin, Richard I. Morimoto, Alfred Lewis Goldberg, Daniel Finley, Christopher T. Walsh, and Randall W. King in 2006 and is headquartered in Boston, MA. | Health Technology |
Fore Biotherapeutics, Inc.
Fore Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Fore Biotherapeutics, Inc. develops tumor specific driver mutations. It offers fully automated live-cell screening from NGS data. The company was founded by Haim Gil-Ad and Yoram Altschuler in 2011 and is headquartered in Philadelphia, PA. | Health Technology |
Vallon Pharmaceuticals, Inc.
 Vallon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Vallon Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It focuses on the development and commercialization of proprietary biopharmaceutical products. The firm's primary product is Abuse-Deterrent Amphetamine Immediate and its product pipeline includes ADAIR, ADMIR, ADHD, and Narcolepsy. The company was founded by David C. Baker on January 11, 2018 and is headquartered in Philadelphia, PA. | Health Technology |
Onsero Therapeutics Inc
Onsero Therapeutics Inc Miscellaneous Commercial ServicesCommercial Services Onsero Therapeutics Inc is a preclinical neurobiology company that focuses on discovering and developing small molecule drugs to treat a range of neuropsychiatric and mental health conditions by targeting G-protein-coupled receptors (GPCRs). The company is based in Boston, MA. The company's mission is to provide safe and convenient pharmaceutical options to patients. Meenu Karson has been the CEO of the company since 2021. | Commercial Services |
Vasomune Therapeutics, Inc.
Vasomune Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Vasomune Therapeutics, Inc. operates as an early stage biopharmaceutical company. It develops medicines to harness the body’s ability to defend against illness by modifying cellular response to disease. The company is headquartered in Toronto, Canada. | Health Technology |
